
Merck & Co. MRK
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
2.5 B |
Market Cap[1] |
$ 368 B |
EBITDA (LTM) |
$ 2.96 B |
P/E (LTM) |
150.29 |
P/S (LTM) |
5.580836 |
EPS (LTM) |
1.0 |
Merck & Co., Inc. is a global pharmaceutical company that specializes in the development, manufacturing, and distribution of innovative medicines, vaccines, and animal health products. Founded in 1891, Merck has grown to become one of the largest pharmaceutical companies in the world, with operations in over 140 countries.
The company's mission is to improve the health and well-being of people and animals around the world. Merck is committed to discovering new treatments and cures for some of the most challenging diseases, including cancer, Alzheimer's disease, and HIV/AIDS. The company has a strong pipeline of products in development, with a focus on immunotherapy and oncology.
Merck is also a leader in the development and distribution of vaccines. The company has played a key role in the fight against infectious diseases such as measles, mumps, rubella, and HPV. Merck's vaccines have saved countless lives around the world and continue to be an important tool in preventing disease outbreaks.
In addition to its pharmaceutical and vaccine business, Merck also has a thriving animal health division. The company develops and manufactures products for livestock, pets, and wildlife. Merck's animal health products are used to prevent and treat diseases in animals, improving their health and welfare.
Merck is committed to operating responsibly and sustainably. The company has set ambitious goals to reduce its environmental impact, improve the health and safety of its employees, and support the communities where it operates. Merck has been recognized for its sustainability efforts, including being named to the Dow Jones Sustainability Index for the past 16 years.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Repare Therapeutics
RPTX
|
- | - | $ 112 M | Nasdaq Global Select Market | ||
|
Sesen Bio
SESN
|
- | 7.29 % | $ 127 M | Nasdaq Global Select Market | ||
|
Windtree Therapeutics
WINT
|
- | - | $ 26.8 M | Nasdaq Global Select Market | ||
|
Trean Insurance Group
TIG
|
- | - | $ 316 M | Nasdaq Global Select Market | ||
|
SQZ Biotechnologies Company
SQZ
|
- | 57.95 % | $ 12.8 M | NYSE | ||
|
MEI Pharma
MEIP
|
- | 10.43 % | $ 20.5 M | Nasdaq Capital Market | ||
|
Palatin Technologies
PTN
|
- | - | $ 13 M | NYSE American | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
ММЦБ
GEMA
|
- | - | - | MOEX | ||
|
Lyra Therapeutics
LYRA
|
- | - | $ 24.9 M | Nasdaq Global Market | ||
|
ОЗОН Фармацевтика
OZPH
|
- | - | - | MOEX | ||
|
Промомед
PRMD
|
- | - | - | MOEX | ||
|
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
ESSA Pharma
EPIX
|
- | - | $ 8.86 M | Nasdaq Capital Market | ||
|
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | ||
|
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | ||
|
Merus N.V.
MRUS
|
- | - | $ 5.78 B | Nasdaq Global Select Market | ||
|
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | ||
|
Annexon
ANNX
|
$ 4.0 | -7.62 % | $ 620 M | Nasdaq Global Select Market | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 156.5 | -2.85 % | $ 20.5 B | Nasdaq Global Select Market,SPB | ||
|
Amgen
AMGN
|
$ 462.71 | -3.3 % | $ 249 B | Nasdaq Global Select Market,SPB | ||
|
Theratechnologies
THTX
|
- | - | $ 83.9 M | Nasdaq Capital Market | ||
|
Iovance Biotherapeutics
IOVA
|
$ 7.72 | -11.26 % | $ 2.76 M | Nasdaq Global Market,SPB | ||
|
Biogen
BIIB
|
$ 243.85 | -4.17 % | $ 35.7 B | Nasdaq Global Select Market,SPB | ||
|
Ironwood Pharmaceuticals
IRWD
|
$ 4.03 | 6.9 % | $ 652 M | Nasdaq Global Select Market | ||
|
Armata Pharmaceuticals
ARMP
|
$ 3.01 | -4.14 % | $ 109 M | NYSE American | ||
|
Mustang Bio
MBIO
|
$ 0.39 | -5.63 % | $ 1.91 M | Nasdaq Global Market | ||
|
MannKind Corporation
MNKD
|
$ 3.77 | -4.07 % | $ 1.15 B | Nasdaq Global Market | ||
|
InflaRx N.V.
IFRX
|
$ 1.36 | -8.11 % | $ 91.5 M | Nasdaq Global Select Market | ||
|
Immutep Limited
IMMP
|
$ 2.7 | -8.47 % | $ 3.93 B | Nasdaq Global Market | ||
|
Insmed Incorporated
INSM
|
$ 108.79 | -1.1 % | $ 21.7 B | Nasdaq Global Select Market | ||
|
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | Nasdaq Capital Market | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
$ 227.25 | -3.16 % | $ 13.9 B | Nasdaq Global Select Market | ||
|
BioLineRx Ltd.
BLRX
|
$ 1.77 | -4.95 % | $ 4.36 B | Nasdaq Capital Market | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 63.15 | -1.64 % | $ 128 B | NYSE,SPB | ||
|
Johnson & Johnson
JNJ
|
$ 272.47 | -1.4 % | $ 656 B | NYSE,SPB | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
PainReform Ltd.
PRFX
|
$ 0.76 | -1.27 % | $ 492 K | Nasdaq Capital Market | ||
|
Kala Pharmaceuticals
KALA
|
$ 0.15 | -13.14 % | $ 1.22 M | Nasdaq Global Select Market | ||
|
Prothena Corporation plc
PRTA
|
$ 7.9 | -5.84 % | $ 425 M | Nasdaq Global Select Market,SPB | ||
|
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | Nasdaq Global Select Market,SPB | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
$ 14.53 | -1.63 % | $ 12.1 B | NYSE | ||
|
Keros Therapeutics
KROS
|
$ 9.42 | -13.02 % | $ 351 M | Nasdaq Global Select Market | ||
|
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | ||
|
Kazia Therapeutics Limited
KZIA
|
$ 7.13 | -11.76 % | $ 109 M | Nasdaq Global Select Market | ||
|
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | Nasdaq Global Select Market | ||
|
Sana Biotechnology
SANA
|
$ 2.32 | -9.38 % | $ 588 M | Nasdaq Global Select Market | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.98 | -4.85 % | $ 226 M | NYSE American | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
$ 298.8 | -5.48 % | $ 5.78 B | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.